IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis

Journal of Immunology

Volumn 192, Issue 5, 2014, Pages 2082-2090

  Merlo, Lauren M F ^a   Pigott, Elizabeth ^a   DuHadaway, James B ^a   Grabler, Samantha ^a   Metz, Richard ^b   Prendergast, George C ^a,c,d   Mandik Nayak, Laura ^a,c  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b NEWLINK GENETICS   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DIOXYGENASE; IMMUNOGLOBULIN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; WILD TYPE;

ANIMALS; ANTIBODY FORMATION; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-LYMPHOCYTES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MICE; MICE, KNOCKOUT; T-LYMPHOCYTES;

EID: 84896502247     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1303012     Document Type: Article

References (62)

1. Townsend, M. J., J. G. Monroe, and A. C. Chan. 2010. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol. Rev. 237: 264-283.
2. Harvey, P. R., and C. Gordon. 2013. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. BioDrugs 27: 85-95.
3. Buch, M. H., J. S. Smolen, N. Betteridge, F. C. Breedveld, G. Burmester, T. Dörner, G. Ferraccioli, J. E. Gottenberg, J. Isaacs, T. K. Kvien, et al; Rituximab Consensus Expert Committee. 2011. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70: 909-920.
4. Helmick, C. G., D. T. Felson, R. C. Lawrence, S. Gabriel, R. Hirsch, C. K. Kwoh, M. H. Liang, H. M. Kremers, M. D. Mayes, P. A. Merkel, et al; National Arthritis DataWorkgroup. 2008. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58: 15-25.
5. Upchurch, K. S., and J. Kay. 2012. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 51(Suppl 6): vi28-vi36.
6. Beetham, W., Jr., S. Fischer, and R. Schrohenloher. 1964. Tryptophan metabolite excretion in connective tissue diseases demonstrating a difference between rheumatoid spondylitis and rheumatoid arthritis. Proc. Soc. Exp. Biol. Med. 117: 756-759.
7. Labadarios, D., D. Y. McKenzie, J. W. Dickerson, and D. V. Parke. 1978. Metabolic abnormalities of tryptophan and nicotinic acid in patients with rheumatoid arthritis. Rheumatol. Rehabil. 17: 227-232.
8. Mandel, E. H., and H. D. Appleton. 1966. Tryptophan metabolism. Results of studies in discoid lupus erythematosus. Arch. Dermatol. 94: 358-360.
9. Spiera, H., and R. Vallarino. 1969. Serum kynurenine in rheumatoid arthritis. J. Clin. Invest. 48: 856-859.
10. Widner, B., N. Sepp, E. Kowald, S. Kind, M. Schmuth, and D. Fuchs. 1999. Degradation of tryptophan in patients with systemic lupus erythematosus. Adv. Exp. Med. Biol. 467: 571-577.
11. Widner, B., N. Sepp, E. Kowald, U. Ortner, B. Wirleitner, P. Fritsch, G. Baier-Bitterlich, and D. Fuchs. 2000. Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 201: 621-630.
12. Furuzawa-Carballeda, J., G. Lima, J. Jakez-Ocampo, and L. Llorente. 2011. Indoleamine 2,3-dioxygenase-expressing peripheral cells in rheumatoid arthritis and systemic lupus erythematosus: a cross-sectional study. Eur. J. Clin. Invest. 41: 1037-1046.
13. Pertovaara, M., T. Hasan, A. Raitala, S. S. Oja, U. Yli-Kerttula, M. Korpela, and M. Hurme. 2007. Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin. Exp. Immunol. 150: 274-278.
14. Munn, D. H., M. Zhou, J. T. Attwood, I. Bondarev, S. J. Conway, B. Marshall, C. Brown, and A. L. Mellor. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191-1193.
15. Elovainio, M., M. Hurme, M. Jokela, L. Pulkki-Raback, M. Kivimäki, M. Hintsanen, T. Hintsa, T. Lehtimäki, J. Viikari, O. T. Raitakari, and L. Keltikangas-Järvinen. 2012. Indoleamine 2,3-dioxygenase activation and depressive symptoms: results from the Young Finns Study. Psychosom. Med. 74: 675-681.
16. Oxenkrug, G. F. 2010. Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr. J. Psychiatry Relat. Sci. 47: 56-63.
17. Xiao, Y., H. Christou, L. Liu, G. Visner, S. A. Mitsialis, S. Kourembanas, and H. Liu. 2013. Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. Am. J. Respir. Crit. Care Med. 188: 482-491.
18. Muller, A. J., and P. A. Scherle. 2006. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer 6: 613-625.
19. Prendergast, G. C., M. Y. Chang, L.Mandik-Nayak, R. Metz, and A. J.Muller. 2011. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-Associated diseases. Curr. Med. Chem. 18: 2257-2262.
20. Gurtner, G. J., R. D. Newberry, S. R. Schloemann, K. G. McDonald, and W. F. Stenson. 2003. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 125: 1762-1773.
21. Sakurai, K., J. P. Zou, J. R. Tschetter, J. M. Ward, and G. M. Shearer. 2002. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 129: 186-196.
22. Szántó, S., T. Koreny, K. Mikecz, T. T. Glant, Z. Szekanecz, and J. Varga. 2007. Inhibition of indoleamine 2,3-dioxygenase- mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res. Ther. 9: R50.
23. Scott, G. N., J. DuHadaway, E. Pigott, N. Ridge, G. C. Prendergast, A. J. Muller, and L. Mandik-Nayak. 2009. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J. Immunol. 182: 7509-7517.
24. Xu, H., T. B. Oriss, M. Fei, A. C. Henry, B. N. Melgert, L. Chen, A. L. Mellor, D. H. Munn, C. G. Irvin, P. Ray, and A. Ray. 2008. Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc. Natl. Acad. Sci. USA 105: 6690-6695.
25. von Bubnoff, D., and T. Bieber. 2012. The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy. Allergy 67: 718-725.
26. Metz, R., C. Smith, J. B. DuHadaway, P. Chandler, B. Baban, L. M. F. Merlo, E. Pigott, M. P. Keough, S. Rust, A. L. Mellor, et al. 2014. IDO2 is critical for IDO1-mediated T cell regulation and exerts a non-redundant function in inflammation. Int. Immunol. In press.
27. Kouskoff, V., A. S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis. 1996. Organ-specific disease provoked by systemic autoimmunity. Cell 87: 811-822.
28. Korganow, A. S., H. Ji, S. Mangialaio, V. Duchatelle, R. Pelanda, T. Martin, C. Degott, H. Kikutani, K. Rajewsky, J. L. Pasquali, et al. 1999. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10: 451-461.
29. Matsumoto, I., A. Staub, C. Benoist, and D. Mathis. 1999. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286: 1732-1735.
30. Mandik-Nayak, L., B. T. Wipke, F. F. Shih, E. R. Unanue, and P. M. Allen. 2002. Despite ubiquitous autoantigen expression, arthritogenic autoantibody response initiates in the local lymph node. Proc. Natl. Acad. Sci. USA 99: 14368-14373.
31. Mewar, D., and A. G. Wilson. 2006. Autoantibodies in rheumatoid arthritis: a review. Biomed. Pharmacother. 60: 648-655.
32. Pigott, E., and L. Mandik-Nayak. 2012. Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K/BxN mice. Arthritis Rheum. 64: 2169-2178.
33. Metz, R., S. Rust, J. B. Duhadaway, M. R. Mautino, D. H. Munn, N. N. Vahanian, C. J. Link, and G. C. Prendergast. 2012. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. OncoImmunology 1: 1460-1468.
34. Metz, R., J. B. Duhadaway, U. Kamasani, L. Laury-Kleintop, A. J. Muller, and G. C. Prendergast. 2007. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 67: 7082-7087.
35. Baban, B., P. Chandler, D. McCool, B. Marshall, D. H. Munn, and A. L. Mellor. 2004. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol. 61: 67-77.
36. Amirkhani, A., E. Heldin, K. E. Markides, and J. Bergquist. 2002. Quantitation of tryptophan, kynurenine and kynurenic acid in human plasma by capillary liquid chromatography-electrospray ionization tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 780: 381-387.
37. Jacob, J., R. Kassir, and G. Kelsoe. 1991. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations. J. Exp. Med. 173: 1165-1175.
38. Ball, H. J., A. Sanchez-Perez, S. Weiser, C. J. Austin, F. Astelbauer, J. Miu, J. A. McQuillan, R. Stocker, L. S. Jermiin, and N. H. Hunt. 2007. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396: 203-213.
39. Qian, F., J. Liao, J. Villella, R. Edwards, P. Kalinski, S. Lele, P. Shrikant, and K. Odunsi. 2012. Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation. Cancer Immunol. Immunother. 61: 2013-2020.
40. Yuasa, H. J., M. Takubo, A. Takahashi, T. Hasegawa, H. Noma, and T. Suzuki. 2007. Evolution of vertebrate indoleamine 2,3-dioxygenases. J. Mol. Evol. 65: 705-714.
41. Hou, D. Y., A. J. Muller, M. D. Sharma, J. DuHadaway, T. Banerjee, M. Johnson, A. L. Mellor, G. C. Prendergast, and D. H. Munn. 2007. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67: 792-801.
42. Ji, H., D. Gauguier, K. Ohmura, A. Gonzalez, V. Duchatelle, P. Danoy, H. J. Garchon, C. Degott, M. Lathrop, C. Benoist, and D. Mathis. 2001. Genetic influences on the end-stage effector phase of arthritis. J. Exp. Med. 194: 321-330.
43. Mandik-Nayak, L., and P. M. Allen. 2005. Initiation of an autoimmune response: insights from a transgenic model of rheumatoid arthritis. Immunol. Res. 32: 5-13.
44. Block, K. E., and H. Huang. 2013. The cellular source and target of IL-21 in K/ BxN autoimmune arthritis. J. Immunol. 191: 2948-2955.
45. Ohmura, K., L. T. Nguyen, R. M. Locksley, D. Mathis, and C. Benoist. 2005. Interleukin-4 can be a key positive regulator of inflammatory arthritis. Arthritis Rheum. 52: 1866-1875.
46. Ji, H., A. Pettit, K. Ohmura, A. Ortiz-Lopez, V. Duchatelle, C. Degott, E. Gravallese, D. Mathis, and C. Benoist. 2002. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J. Exp. Med. 196: 77-85.
47. Genovese, M. C., J. D. McKay, E. L. Nasonov, E. F. Mysler, N. A. da Silva, E. Alecock, T. Woodworth, and J. J. Gomez-Reino. 2008. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58: 2968-2980.
48. Schoels, M. M., D. Van der Heijde, F. C. Breedveld, G. R. Burmester, M. Dougados, P. Emery, G. Ferraccioli, C. Gabay, A. Gibofsky, J. J. Gomez-Reino, et al. 2013. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-Analysis informing a consensus statement. Ann. Rheum. Dis. 72: 583-589.
49. Hickman-Brecks, C. L., J. L. Racz, D. M. Meyer, T. P. LaBranche, and P. M. Allen. 2011. Th17 cells can provide B cell help in autoantibody induced arthritis. J. Autoimmun. 36: 65-75.
50. LaBranche, T. P., C. L. Hickman-Brecks, D. M. Meyer, C. E. Storer, M. I. Jesson, K. M. Shevlin, F. A. Happa, R. A. Barve, D. J. Weiss, J. C. Minnerly, et al. 2010. Characterization of the KRN cell transfer model of rheumatoid arthritis (KRNCTM), a chronic yet synchronized version of the K/BxN mouse. Am. J. Pathol. 177: 1388-1396.
51. Muller, A. J., M. D. Sharma, P. R. Chandler, J. B. Duhadaway, M. E. Everhart, B. A. Johnson, III, D. J. Kahler, J. Pihkala, A. P. Soler, D. H. Munn, et al. 2008. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. USA 105: 17073-17078.
52. Yang, H., R. Ding, V. K. Sharma, F. S. Hilaire, M. Lagman, B. Li, D. A. Thomas, X. Luo, P. Song, C. Stauffer, et al. 2007. Hyperexpression of Foxp3 and IDO during acute rejection of islet allografts. Transplantation 83: 1643-1647.
53. Smith, C., M. Y. Chang, K. H. Parker, D. W. Beury, J. B. DuHadaway, H. E. Flick, J. Boulden, E. Sutanto-Ward, A. P. Soler, L. D. Laury-Kleintop, et al. 2012. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2: 722-735.
54. Meininger, D., L. Zalameda, Y. Liu, L. P. Stepan, L. Borges, J. D. McCarter, and C. L. Sutherland. 2011. Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim. Biophys. Acta 1814: 1947-1954.
55. Fukunaga, M., Y. Yamamoto, M. Kawasoe, Y. Arioka, Y. Murakami, M. Hoshi, and K. Saito. 2012. Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis. J. Histochem. Cytochem. 60: 854-860.
56. Criado, G., E. Simelyte, J. J. Inglis, D. Essex, and R. O. Williams. 2009. Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis. Arthritis Rheum. 60: 1342-1351.
57. Yuasa, H. J., H. J. Ball, C. J. Austin, and N. H. Hunt. 2010. 1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 157: 10-15.
58. Crotty, S. 2011. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29: 621-663.
59. Jang, E., S. H. Cho, H. Park, D. J. Paik, J. M. Kim, and J. Youn. 2009. A positive feedback loop of IL-21 signaling provoked by homeostatic CD4+CD252 T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice. J. Immunol. 182: 4649-4656.
60. Wu, H. J., I. I. Ivanov, J. Darce, K. Hattori, T. Shima, Y. Umesaki, D. R. Littman, C. Benoist, and D. Mathis. 2010. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32: 815-827.
61. Harden, J. L., and N. K. Egilmez. 2012. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol. Invest. 41: 738-764.
62. Nutt, S. L., and D. M. Tarlinton. 2011. Germinal center B and follicular helper T cells: siblings, cousins or just good friends? Nat. Immunol. 12: 472-477.